Today's Breaking News
- Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
- Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
- MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
Latest R&D and Business News
- EUSA Pharma Announces Acquisition of Global Rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC for $115 Million
- Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
- Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis
- SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington's Disease Patients
- Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
- Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
- Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
- Advanced Proteome Therapeutics Announces Collaboration with Noria Pharmaceuticals
- Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study
- Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies
- AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan
- Concentric Analgesics Initiates Phase 2 Clinical Study of CA-008 for the Treatment of Post-Surgical Pain